Chances are you’ve come into contact with a label today. Whether on a breakfast bar, a tube of toothpaste, or a bottle of sunscreen, labels are part of our daily lives and provide important health information and directions to keep us safe.

Medications to prevent migraine have been slow in coming, but a treatment approach currently being studied suggests that a new type of drug may benefit countless migraineurs. This new method employs agents that block a protein called calcitonin gene-related peptide (CGRP), which plays a crucial role in migraine. The new drugs, anti-CGRP antibodies, bind to the protein and stop it from attaching to nerve receptors, preventing migraine in the process.

Pregnant women should not use certain preventive migraine medications because the drugs have been linked to lower IQ scores in children who were exposed to these drugs in the womb, according to the U.S. Food and Drug Administration (FDA). Pregnant women should avoid taking valproate sodium and related medications. Valproate products include valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP and Depakote ER), valproic acid (Depakene and Stavzor) and their generics.

Merck & Co., Inc. has been pursuing a new migraine medication, called telcagepant, which blocks the action of a chemical called calcitonin gene-related peptide, or CGRP. CGRP has been implicated in migraine in a number of studies. The drug, which has completed phase III studies, has been heralded as an exciting advance because it's a completely new compound that is not a vasoconstrictor, unlike the triptan drugs, so is less likely to cause cardiovascular issues in those with pre-existing risk factors.